HCPLive Network

Three New Treatments Show Promise for Parkinson's Disease

FRIDAY, March 15 (HealthDay News) -- Three new treatments show promise for patients with Parkinson's disease, according to three studies to be presented at the annual meeting of the American Academy of Neurology, held from March 16 to 23 in San Diego.

Stuart Isaacson, MD, from the University of South Florida, in Tampa, and colleagues randomized 225 patients with Parkinson's disease to receive placebo or droxidopa, an oral pro-drug converted to norepinephrine, for an eight-week treatment period. The researchers found that, at week one, patients receiving droxidopa experienced significant improvement in dizziness/lightheadedness, with a trend toward improvement at week eight. There was a significant improvement in standing systolic blood pressure at week one with droxidopa, and a numerical improvement at week eight.

C. Warren Olanow, MD, from the Mount Sinai School of Medicine, in New York City, and colleagues randomized 337 patients with stable dosages of levodopa to tozadenant (60, 120, 180, or 240 mg twice daily) or placebo. The researchers found that patients in the 120 mg and 180 mg tozadenant groups experienced significant reductions in OFF time at 12 weeks, compared with baseline, with no increase in ON time with troublesome dyskinesia. In a third study, Robert A. Hauser, MD, of the University of South Florida, in Tampa, and colleagues found that, for patients receiving dopamine agonist monotherapy with suboptimal symptom control, treatment with add-on rasagiline resulted in a significant improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) score and in UPDRS-motor scores compared with placebo.

"All of these treatments are promising news for people with Parkinson's disease, which is the second most common neurodegenerative disease after Alzheimer's disease," Hauser said in a statement.

The first, second, and third studies were funded by Chelsea Therapeutics, Biotie Therapies, and Teva Pharmaceuticals, respectively.

Abstract - Isaacson
Abstract - Olanow
Abstract - Hauser
More Information

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Provocative research raises the question of whether we should we look at Alzheimer’s disease as “type 3 diabetes.”
In remarks delivered at the American Academy of Family Physicians 2014 Assembly, HHS Secretary Sylvia Mathews Burwell spoke about the ongoing response to the Ebola outbreak, improving health care delivery, the Affordable Care Act, and the Transforming Clinical Practice Initiative.
New York and New Jersey health officials announced today that all health care workers returning from caring for patients in Ebola hot zones in West Africa will have to go into quarantine for 21 days. The new policy is stricter than the current one recommended by the US Centers for Disease Control and Prevention that calls for health monitoring for 21 days. It was that policy that allowed Craig Spencer, MD to be out and about a day before he was diagnosed with Ebola Thursday and rushed to city-run Bellevue Hospital Center in Manhattan.
For stroke survivors, annual direct costs are comparable at 10 years and between 3 to 5 years for ischemic stroke but are higher at 10 years after hemorrhagic stroke, according to a study published online Oct. 23 in Stroke.
A non-inferiority study published in the October 6, 2014 issue of JAMA Internal Medicine looks at these drugs. The researchers report that prescribing β-lactam monotherapy may be as effective as the combination of a macrolide with a β-lactam in certain patients.
Targets of workplace bullying can offer chaos, report, or quest narratives about their experiences, and coworker response plays a role in narrative development, according to a study published online Sept. 25 in Management Communication Quarterly.
Hypoglycemia related to type 2 diabetes mellitus (T2DM) doesn't appear to impact brain pathology, according to a study published online Sept. 29 in Diabetes Care.
More Reading
Provocative research raises the question of whether we should we look at Alzheimer’s disease as “type 3 diabetes.”